123 related articles for article (PubMed ID: 29721084)
1. A novel USP9X substrate TTK contributes to tumorigenesis in non-small-cell lung cancer.
Chen X; Yu C; Gao J; Zhu H; Cui B; Zhang T; Zhou Y; Liu Q; He H; Xiao R; Huang R; Xie H; Gao D; Zhou H
Theranostics; 2018; 8(9):2348-2360. PubMed ID: 29721084
[TBL] [Abstract][Full Text] [Related]
2. TTK/hMPS1 is an attractive therapeutic target for triple-negative breast cancer.
Maire V; Baldeyron C; Richardson M; Tesson B; Vincent-Salomon A; Gravier E; Marty-Prouvost B; De Koning L; Rigaill G; Dumont A; Gentien D; Barillot E; Roman-Roman S; Depil S; Cruzalegui F; Pierré A; Tucker GC; Dubois T
PLoS One; 2013; 8(5):e63712. PubMed ID: 23700430
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic targeting of the TPX2/TTK network in colorectal cancer.
Shaath H; Vishnubalaji R; Elango R; Velayutham D; Jithesh PV; Alajez NM
Cell Commun Signal; 2023 Sep; 21(1):265. PubMed ID: 37770979
[TBL] [Abstract][Full Text] [Related]
4. CWH43 Is a Novel Tumor Suppressor Gene with Negative Regulation of TTK in Colorectal Cancer.
Lee CC; Tsai KY; Lee AW; Wei PL; Huang CY; Batzorig U; Chang YJ
Int J Mol Sci; 2023 Oct; 24(20):. PubMed ID: 37894942
[TBL] [Abstract][Full Text] [Related]
5. USP9X-mediated REV1 deubiquitination promotes lung cancer radioresistance via the action of REV1 as a Rad18 molecular scaffold for cystathionine γ-lyase.
Chen Y; Feng X; Wu Z; Yang Y; Rao X; Meng R; Zhang S; Dong X; Xu S; Wu G; Jie X
J Biomed Sci; 2024 May; 31(1):55. PubMed ID: 38802791
[TBL] [Abstract][Full Text] [Related]
6. Stabilization of PTGES by deubiquitinase USP9X promotes metastatic features of lung cancer via PGE
Wang T; Jing B; Sun B; Liao Y; Song H; Xu D; Guo W; Li K; Hu M; Liu S; Ling J; Kuang Y; Feng Y; Zhou BP; Deng J
Am J Cancer Res; 2019; 9(6):1145-1160. PubMed ID: 31285948
[TBL] [Abstract][Full Text] [Related]
7. Discovery of a potent and selective covalent threonine tyrosine kinase (TTK) inhibitor.
Sun Y; Chen Z; Liu G; Chen X; Shi Z; Feng H; Yu L; Li G; Ding K; Huang H; Zhang Z; Xu S
Bioorg Chem; 2024 Feb; 143():107053. PubMed ID: 38159497
[TBL] [Abstract][Full Text] [Related]
8. Cellular functions, molecular signalings and therapeutic applications: Translational potential of deubiquitylating enzyme USP9X as a drug target in cancer treatment.
Gao H; Chen Z; Zhao L; Ji C; Xing F
Biochim Biophys Acta Rev Cancer; 2024 May; 1879(3):189099. PubMed ID: 38582329
[TBL] [Abstract][Full Text] [Related]
9. The TDRD3-USP9X complex and MIB1 regulate TOP3B homeostasis and prevent deleterious TOP3B cleavage complexes.
Saha S; Huang SN; Yang X; Saha LK; Sun Y; Khandagale P; Jenkins LM; Pommier Y
Nat Commun; 2023 Nov; 14(1):7524. PubMed ID: 37980342
[TBL] [Abstract][Full Text] [Related]
10. Roles of USP9X in cellular functions and tumorigenesis (Review).
Meng Y; Hong C; Yang S; Qin Z; Yang L; Huang Y
Oncol Lett; 2023 Dec; 26(6):506. PubMed ID: 37920433
[TBL] [Abstract][Full Text] [Related]
11. Abrogation of USP9X Is a Potential Strategy to Decrease PEG10 Levels and Impede Tumor Progression in Cutaneous T-Cell Lymphoma.
Xiong S; Liu F; Sun J; Gao S; Wong CCL; Tu P; Wang Y
J Invest Dermatol; 2024 Apr; ():. PubMed ID: 38677662
[TBL] [Abstract][Full Text] [Related]
12. The deubiquitinase USP9X regulates RIT1 protein abundance and oncogenic phenotypes.
Riley AK; Grant M; Snell A; Vichas A; Moorthi S; Urisman A; Castel P; Wan L; Berger AH
bioRxiv; 2023 Dec; ():. PubMed ID: 38077017
[No Abstract] [Full Text] [Related]
13. Bilateral Cataracts and Posterior Lentiglobus in USP9X Syndrome.
Hwang ES; Harrie RP; Desautels J
Ophthalmology; 2023 Dec; ():. PubMed ID: 38099911
[No Abstract] [Full Text] [Related]
14. Correction: The deubiquitylase USP9X controls ribosomal stalling.
Clancy A; Heride C; Pinto-Fernández A; Elcocks H; Kallinos A; Kayser-Bricker KJ; Wang W; Smith V; Davis S; Fessler S; McKinnon C; Katz M; Hammonds T; Jones NP; O'Connell J; Follows B; Mischke S; Caravella JA; Ioannidis S; Dinsmore C; Kim S; Behrens A; Komander D; Kessler BM; Urbé S; Clague MJ
J Cell Biol; 2021 Mar; 220(3):. PubMed ID: 33600552
[No Abstract] [Full Text] [Related]
15. Identification of a USP9X Substrate NFX1-123 by SILAC-Based Quantitative Proteomics.
Chen X; Lu D; Gao J; Zhu H; Zhou Y; Gao D; Zhou H
J Proteome Res; 2019 Jun; 18(6):2654-2665. PubMed ID: 31059266
[TBL] [Abstract][Full Text] [Related]
16. TTK promotes mesenchymal signaling via multiple mechanisms in triple negative breast cancer.
King JL; Zhang B; Li Y; Li KP; Ni JJ; Saavedra HI; Dong JT
Oncogenesis; 2018 Sep; 7(9):69. PubMed ID: 30206215
[TBL] [Abstract][Full Text] [Related]
17. USP9X-mediated KDM4C deubiquitination promotes lung cancer radioresistance by epigenetically inducing TGF-β2 transcription.
Jie X; Fong WP; Zhou R; Zhao Y; Zhao Y; Meng R; Zhang S; Dong X; Zhang T; Yang K; Wu G; Xu S
Cell Death Differ; 2021 Jul; 28(7):2095-2111. PubMed ID: 33558705
[TBL] [Abstract][Full Text] [Related]
18. Bioinformatics analysis and experimental validation of TTK as a biomarker for prognosis in non-small cell lung cancer.
Chen J; Wu R; Xuan Y; Jiang M; Zeng Y
Biosci Rep; 2020 Oct; 40(10):. PubMed ID: 32969465
[TBL] [Abstract][Full Text] [Related]
19. USP9X deubiquitinates connexin43 to prevent high glucose-induced epithelial-to-mesenchymal transition in NRK-52E cells.
Sun XH; Xiao HM; Zhang M; Lin ZY; Yang Y; Chen R; Liu PQ; Huang KP; Huang HQ
Biochem Pharmacol; 2021 Jun; 188():114562. PubMed ID: 33857489
[TBL] [Abstract][Full Text] [Related]
20. Dual TTK/CLK2 inhibitor, CC-671, selectively antagonizes ABCG2-mediated multidrug resistance in lung cancer cells.
Wu ZX; Yang Y; Wang G; Wang JQ; Teng QX; Sun L; Lei ZN; Lin L; Chen ZS; Zou C
Cancer Sci; 2020 Aug; 111(8):2872-2882. PubMed ID: 32478948
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
